NCT02201329 - Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

September 30, 2015

Conditions

Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic

Interventions

DRUG

Azacitidine

Azacitidine (subcutaneous)

DRUG

Volasertib

Volasertib escalating doses (intravenous)

Trial Locations (4)

Boehringer Ingelheim Investigational Site, Aichi, Nagoya

Boehringer Ingelheim Investigational Site, Gunma, Maebashi

Boehringer Ingelheim Investigational Site, Nagasaki, Nagasaki

Boehringer Ingelheim Investigational Site, Tokyo, Sinagawa-ku